The history and future of pharmacogenetics in Aotearoa/New Zealand

被引:0
|
作者
Kennedy, Martin A. [1 ,2 ]
机构
[1] Univ Otago, Carney Ctr Pharmacogen, Christchurch, New Zealand
[2] Univ Otago, Dept Pathol & Biomed Sci, Gene Struct & Funct Lab, Christchurch, New Zealand
关键词
Adverse drug reaction; direct-to-consumer; drug prescribing; genetic test; personalised medicine; pharmacogenomics; MALIGNANT HYPERTHERMIA; PERSONALIZED MEDICINE; CYP2C19; VARIANTS; POLYMORPHISM; GENOTYPE; CYP2D6; METHYLTRANSFERASE; GENE; IMPLEMENTATION; DEBRISOQUINE;
D O I
10.1080/03036758.2024.2406824
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Pharmacogenetics is the study of genetic variants in genes which may impact on the outcome of drug treatment, either through safety considerations (occurrence of adverse drug reactions or therapeutic failure) or altered drug pharmacokinetics. This paper provides a brief history of pharmacogenetics research in the Aotearoa/New Zealand context, and a commentary on our current state. Factors that have limited translation of pharmacogenetic knowledge into ou r healthcare system are considered, and possible solutions to these are proposed. Pharmacogenetic knowledge has long been invoked as a way to improve the safety and success of drug prescribing, but (with some notable exceptions) it has largely failed to achieve this promise. Several barriers to clinical implementation need to be overcome to ensure that pharmacogenetics becomes a key component of precision health for all people in Aotearoa/New Zealand.
引用
收藏
页数:18
相关论文
共 50 条